US FDA Delay For Abecma In Early MM Gives Carvykti Time To Catch Up

Bristol Myers and 2seventy bio are hoping Abecma will be the first CAR-T therapy for earlier lines of multiple myeloma, but an advisory committee meeting will hold up the sBLA.

delayed sign
• Source: Shutterstock

The US Food and Drug Administration will hold an Oncologic Drugs Advisory Committee (ODAC) meeting to review Bristol Myers Squibb Company and 2seventy Bio, Inc.’s supplemental biologics license application (sBLA) for the CAR-T therapy Abecma (idecabtagene vicleucel) for earlier lines of multiple myeloma, meaning it will miss the the 16 December FDA action date.

Key Takeaways
  • The FDA plans to convene an advisory committee to review approval of Abecma in earlier lines of multiple myeloma therapy, and will miss the original user fee deadline.

The companies announced the update on 20 November and said an advisory committee meeting date has not been set. The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

More from Therapy Areas

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By 

Lynkuet will compete with Astellas's Veozah/Veoza

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.